检索结果-南通市图书馆

Effects of Adalimumab Entering National Reimbursement on Medical Costs for Patients With Psoriasis:A 4-Year Single-center Retrospective Study in China

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of dermatology and Venereology 2024年第2期7卷 84-88页

作者： Yu Li Bo-Kun Zhu Qing-Sheng Min Mei Ju Min Li Department of Medical Affairs Hospital for Skin Diseases(Institute of Dermatology)Chinese Academy of Medical Sciences and Peking Union Medical CollegeNanjingJiangsu 210042China Hospital Network Information center Hospital for Skin Diseases(Institute of Dermatology)Chinese Academy of Medical Sciences and Peking Union Medical CollegeNanjingJiangsu 210042China Department of Physiotherapy Hospital for Skin Diseases(Institute of Dermatology)Chinese Academy of Medical Sciences and Peking Union Medical CollegeNanjingJiangsu 210042China Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs Hospital for Skin Diseases(Institute of Dermatology)Chinese Academy of Medical Sciences and Peking Union Medical CollegeNanjingJiangsu 210042China

Objective:Adalimumab(ADA)is expensive and rarely used among ***,its cost for moderate to severe chronic plaque psoriasis can now be reimbursed since its addition to the National Reimbursement Drug List(NRDL)in January ***,we conducted this study to estimate the medical cost of ADA and its influencing factors in patients with psoriasis using ADA and thus gain a better understanding of the effect of the NRDL adjustment in ***:This retrospective study evaluated the medical cost of ADA before and after the addition of ADA to the NRDL(2018—2022)among 320 patients in a large professional dermatology specialty *** analysis,Welch’s analysis of variance,and multiple regression analysis were used to evaluate the medical cost and influencing ***:Before ADA was added to the NRDL,patients’mean total cost and ADA cost were¥24,243.56±16,346.53 and¥20,391.11±14,440.69,*** ADA became covered by the NRDL,the above 2 expenses decreased to¥10,461.19±7,554.66 and¥8,775.27±7,092.16,*** significant decrease in the cost of ADA resulted in a significant 110.5-times increase in ADA *** significant differences were found in the total cost,patient type(outpatient/inpatient),insurance status(yes/no),reimbursement status(before/after),and *** insurance reimbursement(P<0.001,β=-0.468,before reimbursement=1,after reimbursement=2)was the most significant influencing factor,followed by patient type(P=0.018,β=-0.215,outpatient=1,inpatient=2)and age(P=0.0046,β=-0.174).Conclusion:Medical insurance reimbursement is the most important factor affecting patients’total cost of ADA by reducing the economic burden,enhancing the availability of ADA,and stimulating the need for treatment.

关键词： adalimumab biological agent psoriasis medical cost medical insurance

Reevaluation by the CRISPR/Cas9 knockout approach revealed that multiple pluripotency-associated lncRNAs are dispensable for pluripotency maintenance while Snora73a/b is essential for pluripotency exit

在线全文

学校读者我要写书评

暂无评论

Science China Life Sciences 2024年第10期67卷 2198-2212页

作者： Zhen Li Xuefei Li Jingxia Lin Yangming Wang Huiqing Cao Jiajian Zhou Institute of Molecular Medicine College of Future TechnologyPeking University dermatology Hospital Southern Medical University Beijing Advanced center of RNA Biology (BEACON) Peking University

Many long noncoding RNAs(lncRNAs) have been identified through siRNA-based screening as essential regulators of embryonic stem cell(ESC) pluripotency. However, the biological and molecular functions of most lncRNAs remain unclear. Here, we employed CRISPR/Cas9-mediated knockout technology to explore the functions of 8 lncRNAs previously reported to promote pluripotency in mouse ESCs. Unexpectedly, all of these lncRNAs were dispensable for pluripotency maintenance and proliferation in mouse ESCs when disrupted individually or in combination. Single-cell transcriptomic analysis also showed that the knockout of these lncRNAs has a minimal impact on pluripotency gene expression and cell identity. We further showed that several small hairpin RNAs(shRNAs) previously used to knock down lncRNAs caused the downregulation of pluripotency genes in the corresponding lncRNA-knockout ESCs, indicating that off-target effects likely responsible for the pluripotency defects caused by these shRNAs. Interestingly, linc1343-knockout and linc1343-knockdown ESCs failed to form cystic structures and exhibited high expression of pluripotency genes during embryoid body(EB) differentiation. By reintroducing RNA products generated from the linc1343 locus, we found that two snoRNAs, Snora73a and Snora73b, but not lncRNAs, could rescue pluripotency silencing defects during EB differentiation of linc1343 knockout ESCs. Our results suggest that the 8 previously annotated pluripotency-regulating lncRNAs have no overt functions in conventional ESC culture; however, we identified snoRNA products derived from an annotated lncRNA locus as essential regulators for silencing pluripotency genes.

关键词： long noncoding RNAs embryonic stem cells CRISPR/Cas9 snoRNAs stem cell differentiation

同方期刊数据库

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients:A 12-week randomized placebo-controlled phase III trial with long-term extension

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第10期137卷 1190-1198页

作者： Chen Yu Songmei Geng Bin Yang Yunhua Deng Fuqiu Li Xiaojing Kang Mingye Bi Furen Zhang Yi Zhao Weili Pan Zhongwei Tian Jinhua Xu Zhenghua Zhang Nan Yu Xinsuo Duan Shuping Guo Qing Sun Weiquan Li Juan Tao Zhijun Liu Yuanyuan Yin Gang Wang Department of dermatology Xijing HospitalThe Fourth Military Medical UniversityXi’anShaanxi 710032China Department of dermatology The Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShaanxi 710004China Department of dermatology Dermatology Hospital of Southern Medical UniversityGuangzhouGuangdong 510091China Department of dermatology Tongji HospitalHuazhong University of Science and TechnologyWuhanHubei 430030China Department of dermatology The Second Hospital of Jilin UniversityChangchunJilin 130041China Department of dermatology People’s Hospital of Xinjiang Uygur Autonomous RegionUrumqiXinjiang 830001China Department of dermatology Wuxi People’s Hospital of Wuxi CityWuxiJiangsu 214023China Department of dermatology Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of Dermatology and VenereologyShandong First Medical University&Shandong Academy of Medical SciencesJinanShandong 250022China Department of dermatology Beijing Tsinghua Changgung HospitalBeijing 102218China Department of dermatology Zhejiang Provincial People’s HospitalHangzhouZhejiang 310014China Department of dermatology The First Affiliated Hospital of Xinxiang Medical CollegeXinxiangHenan 453100China Department of dermatology Huashan Hospital Affiliated to Fudan UniversityShanghai 200040China Department of dermatology General Hospital of Ningxia Medical UniversityYinchuanNingxia 750000China Department of dermatology Affiliated Hospital of Chengde Medical UniversityChengdeHebei 067000China Department of dermatology The First Hospital of Shanxi Medical UniversityTaiyuanShanxi 030001China Department of dermatology Qilu Hospital of Shandong UniversityJinanShandong 250012China Department of dermatology Yuebei People’s HospitalShaoguanGuangdong 512026China Department of dermatology Union Hospital Tongji Medical Collage Huazhong University of Science and TechnologyWuhanHubei 430022China Department of dermatology and Venereal Diseases The First Affiliated Hospit

Background:There is a need for effective and safe therapies for psoriasis that provide sustained *** aim of this study was to assess the efficacy and safety of tildrakizumab,an anti-interleukin-23p19 monoclonal antibody,for treating moderate-to-severe plaque psoriasis in Chinese ***:In this multi-center,double-blind,phase III trial,patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned(1:1)to receive subcutaneous tildrakizumab 100 mg or placebo at weeks 0 and *** initially assigned to placebo were switched to receive tildrakizumab at weeks 12,16,and every 12 weeks *** in the tildrakizumab group continued with tildrakizumab at week 16,and every 12 weeks until week *** primary endpoint was the Psoriasis Area and Severity Index(PASI 75)response rate at week ***:At week 12,tildrakizumab demonstrated significantly higher PASI 75 response rates(66.4%[73/110]vs.12.7%[14/110];difference,51.4%[95%confidence interval(CI),40.72,62.13];P<0.001)and Physician’s Global Assessment(60.9%[67/110]vs.10.0%[11/110];difference,49.1%[95%CI,38.64,59.62];P<0.001)compared to *** 75 response continued to improve over time in both tildrakizumab and placebo-switching to tildrakizumab groups,reaching maximal efficacy after 28 weeks(86.8%[92/106]vs.82.4%[89/108])and maintained up to 52 weeks(91.3%[95/104]vs.87.4%[90/103]).Most treatment-emergent adverse events were mild and not related to ***:Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque *** registration:***,NCT05108766.

关键词： Tildrakizumab Interleukin 23 Plaque psoriasis Chinese Randomized controlled trial

Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis:A multicenter,randomized,double-blind,placebo-controlled phase 2b trial

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第2期137卷 200-208页

作者： Yan Zhao Jianzhong Zhang Bin Yang Jingyi Li Yangfeng Ding Liming Wu Litao Zhang Jinyan Wang Xiaohong Zhu Furen Zhang Xiaohua Tao Yumei Li Chunlei Zhang Linfeng Li Jianyun Lu Qingchun Diao Qianjin Lu Xiaoyong Man Fuqiu Li Xiujuan Xia Hao Cheng Yingmin Jia Guoqing Zhao Jinchun Yan Bo Chen Department of dermatology Peking University People’s HospitalBeijing 100044China Department of dermatology Dermatology HospitalSouthern Medical UniversityGuangzhouGuangdong 510091China Department of dermatology West China HospitalSichuan UniversityChengduSichuan 610041China Department of dermatology Shanghai Skin Disease HospitalInstitute of PsoriasisTongji University School of MedicineShanghai 200443China Department of dermatology Affiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhouZhejiang 310006China Department of dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalTianjin 300120China Department of dermatology Ningbo No.2 HospitalNingboZhejiang 315010China Department of dermatology The Wuxi Second Affiliated Hospital of Nanjing Medical UniversityWuxiJiangsu 214002China Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of dermatology and Veneorology Shandong First Medical University&Shandong Academy of Medical SciencesJinanShandong 250022China center for Plastic&Reconstructive Surgery Department of DermatologyZhejiang Provincial People’s Hospital(Affiliated People’s HospitalHangzhou Medical College)HangzhouZhejiang 310014China Department of dermatology Affiliated Hospital of Jiangsu UniversityZhenjiangJiangsu 212001China Department of dermatology Peking University Third HospitalBeijing 100191China Department of dermatology Beijing Friendship HospitalCapital Medical UniversityBeijing 100050China Department of dermatology The Third Xiangya Hospital of Central South UniversityChangshaHunan 410013China Department of dermatology Chongqing Traditional Chinese Medicine HospitalChongqing 400011China Hunan Key Laboratory of Medical Epigenomics Department of DermatologyThe Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China Department of dermatology The Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiang 310009China Departme

Background:Atopic dermatitis(AD)affects approximately 10%of adults ***310 is a humanized monoclonal antibody targeting interleukin-4 receptor alpha that blocks interleukin-4 and interleukin-13 *** trial aimed to evaluate the efficacy and safety of CM310 in Chinese adults with moderate-to-severe ***:This multicenter,randomized,double-blind,placebo-controlled,phase 2b trial was conducted in 21 medical institutions in China from February to November *** 120 eligible patients were enrolled and randomized(1:1:1)to receive subcutaneous injections of 300 mg CM310,150 mg CM310,or placebo every 2 weeks for 16 weeks,followed by an 8-week follow-up *** primary endpoint was the proportion of patients achieving≥75%improvement in the Eczema Area and Severity Index(EASI-75)score from baseline at week *** and pharmacodynamics were also ***:At week 16,the proportion of EASI-75 responders from baseline was significantly higher in the CM310 groups(70%[28/40]for high-dose and 65%[26/40]for low-dose)than that in the placebo group(20%[8/40]).The differences in EASI-75 response rate were 50%(high ***,95%CI 31%-69%)and 45%(low ***,95%CI 26%-64%),with both P valuesdermatology Life Quality Index compared with ***310 treatment reduced levels of thymus and activation-regulated chemokine,total immunoglobulin E,lactate dehydrogenase,and blood *** incidence of treatment-emergent adverse events(TEAEs)was similar among all three groups,with the most common TEAEs reported being upper respiratory tract infection,atopic dermatitis,hyperlipidemia,and *** severe adverse events were deemed to be attributed to ***:CM310 at 150 mg and 300 mg every 2 weeks demonstrated significant efficacy and was well-tol

关键词： CM310 Moderate-to-severe atopic dermatitis Interleukin-4 receptor alpha Adults

Comorbidities of prurigo nodularis in Chinese patients:A multicenter retrospective study

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第11期137卷 1360-1362页

作者： Mengting Yin Weilong Zhong Keren Zhou Xia Dou Department of dermatology Peking University Shenzhen HospitalShenzhenGuangdong 518036China National Clinical Research center for Skin and Immune Diseases Beijing 100034China

Prurigo nodularis(PN),as a subtype of chronic prurigo(CPG),is characterized by nodular lesions and severe pruritus,which signicantly affect patients’quality of life.[1]It has been observed that patients with PN often have comorbidities,including physical and mental diseases.[2]However,information on comorbidities in Chinese PN patients is *** study aims toll this gap by using a representative patient population to provide comprehensive data on comorbidities in Chinese patients with PN.

关键词： patients morbid lesions

Current status of cognition and skin care behavior in adolescent patients with acne:A survey in China

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第4期137卷 476-477页

作者： Jing Tian Hong Shu Qiufang Qian Zhong Shen Chunyu Zhao Li Song Ping Li Xiuping Han Hua Qian Jinping Chen Hua Wang Lin Ma Yuan Liang Department of dermatology Beijing Children’s HospitalCapital Medical UniversityNational Center for Children’s HealthBeijing 100045China Department of dermatology Kunming Children’s HospitalKunmingYunnan 650034China Department of dermatology Children’s Hospital of ShanghaiChildren’s Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200127China Loreal China Co. LtdShanghai 200040China Department of dermatology Henan Children’s HospitalChildren’s Hospital Affiliated to Zhengzhou UniversityZhengzhou Hospital Beijing Children’s HospitalZhengzhou Children’s HospitalZhengzhouHenan 450052China Department of dermatology Shenzhen Children’s HospitalShenzhenGuangdong 518026China Department of dermatology Shengjing Hospital of China Medical UniversityShenyangLiaoning 110004China Department of dermatology Children’s Hospital of Soochow UniversitySuzhouJiangsu 215025China Department of dermatology Guangzhou Women and Children's Medical CenterGuangzhouGuangdong 510623China Department of dermatology Children’s Hospital of Chongqing Medical UniversityChongqing 400014China

To the Editor:Acne vulgaris(AV)is a common inflammatory skin ***-based epidemiological studies have reported associations between dietary habits,lifestyle factors,family history,and the occurrence and development of acne.^([1–4])This study investigated the skincare behavior and cognition of patients with AV regarding predisposing factors using a designed electronic questionnaire.

关键词： patients dietary behavior

Two hits are better than one:rational dual strategy efficiently fights neuroblastoma

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2024年第5期9卷 1802-1804页

作者： Jacques Zimmer Camille Rolin Markus Ollert Department of Infection and Immunity Luxembourg Institute of HealthEsch-sur-AlzetteLuxembourg University of Luxembourg Esch-sur-AlzetteLuxembourg Department of dermatology and Allergy center Odense Research Center for Anaphylaxis(ORCA)University of Southern DenmarkOdenseDenmark

The recently published landmark paper by Bergaggio et *** Roberto Chiarle’s group in Cancer Cell1 investigates an elegant double-hit strategy to improve anti-cancer *** important approach demonstrates in a preclinical model that chimeric antigen receptor(CAR)-T cell treatment can be rendered more efficient by increasing the cell surface expression of the CAR target structure via a small molecule.

关键词： neuroblastoma Cancer

Major Clinical Features and Epidemic Characteristics of Erosive Vulvar Lichen Planus:A Retrospective Analysis

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of dermatology and Venereology 2024年第2期7卷 94-98页

作者： Ya-Kun Shao Kai-Lyu Sun Min Yang Wan Liu Yu Fu Jian-Min Chang Department of dermatology Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical SciencesBeijing 100730China

Objective:Vulvar lichen planus(VLP),especially erosive VLP(EVLP),seriously affects women’s physiological function and quality of life.A retrospective analysis of erosive vulvar lichen planus(EVLP)was performed to raise awareness on this chronic,deforming,and painful vulvar ***:This observational retrospective study involved 40 patients with EVLP among 1,368 patients with vulvar disease from 2017 to *** patients’vulvar clinical features and extravulvar mucosal involvement were *** patients’pain and quality of life were evaluated with the numeric rating scale and the dermatology Life Quality Index(DLQI),*** characteristics were reported using frequencies and proportions for categorical *** variables are expressed as mean±standard *** association between NRS score for pain and DLQI score was analyzed by Pearson’s correlation ***:EVLP accounted for 2.9%(40/1,368)of all cases of vulvar disease,and the median age at onset was 42 *** mostly occurred on the labia minora and ***(20/40)of the patients had extravulvar mucosal ***(42.5%)patients had oral lichen planus,and seven(17.5%)patients were diagnosed with vulvovaginal-gingival *** numeric rating scale score showed that 47.5%(19/40)of patients experienced mild pain,whereas 12.5%(5/40)described the pain as ***-one patients(77.5%,31/40)had dyspareunia,and nine patients had aggravated pain after sexual *** mean DLQI score was 9.1±6.0,with 37.5%(15/40)of patients indicating that EVLP had severely affected their *** numeric rating scale score for pain was significantly correlated with the DLQI score(P=0.007).Conclusion:EVLP can affect the quality of women’s lives and cause severe deformations and painful architectural *** description of the characteristics of EVLP in this report will benefit the diagnosis and early treatment of this disease.

关键词： erosive vulvar lichen planus multiple mucosal involvement pain assessment quality of life dermatology Life Quality Index numeric rating scale

Self-assembly multifunctional DNA tetrahedron for efficient elimination of antibiotic-resistant bacteria

在线全文

学校读者我要写书评

暂无评论

Aggregate

Aggregate 2024年第1期5卷 204-215页

作者： Tiantian Wu Yu Fu Shuang Guo Yanqiang Shi Yuxin Zhang Zhijin Fan Bin Yang Baoquan Ding Yuhui Liao Molecular Diagnosis and Treatment center for Infectious Diseases Dermatology HospitalSouthern Medical UniversityGuangzhouChina CAS Key Laboratory of Nanosystem and Hierarchical Fabrication CAS Center for Excellence in NanoscienceNational Center for Nanoscience and TechnologyBeijingChina Longgang District Central Hospital of Shenzhen ShenzhenChina

Antibiotic resistance is a major challenge in the clinical treatment of bacterial infectious ***,we constructed a multifunctional DNA nanoplatform as a versatile carrier for bacteria-specific delivery of clinical antibiotic ciprofloxacin(CIP)and classic nanoantibiotic silver nanoparticles(AgNP).In our rational design,CIP was efficiently loaded in the self-assembly double-bundle DNA tetrahedron through intercalation with DNA duplex,and single-strand DNA-modified AgNP was embedded in the cavity of the DNA tetrahedron through *** the site-specific assembly of targeting aptamer in the well-defined DNA tetrahedron,the bacteria-specific dual-antibiotic delivery system exhibited excellent combined bactericidal *** enhanced antibiotic accumulation through breaking the out membrane of bacteria,the antibiotic delivery system effectively inhibited biofilm formation and promoted the healing of infected wounds in *** DNAbased antibiotic delivery system provides a promising strategy for the treatment of antibiotic-resistant infections.

关键词： antibiotic resistance anti-infection therapy biofilm DNA nanotechnology targeted delivery